MRSA Clinical Trials
Here are the 2 most popular medical studies for mrsa
Cefazolin +1 More for Surgical Site Infection
The study is a randomized double-blinded study comparing ceftaroline to standard of care therapy with cefazolin and vancomycin as surgical prophylaxis for high risk orthopedic and cardiac surgeries. Study participants will be enrolled from those undergoing cardiothoracic surgery involving sternotomy and those undergoing prosthetic joint replacement of either hip or knee. Consenting patients will be randomized 2:1 to receive either ceftaroline or cefazolin/vancomycin. This study will be blinded by the use of placebo vancomycin infusions and placebo cephalosporin infusions. The primary end point will be the development of a surgical site infection within 30 days of surgery.
Mrsa Clinical Trials With No Placebo
View 9 mrsa medical studies that do not have a placebo group.
Vancomycin Dosing for MRSA Infections
This trial will compare two vancomycin dosing strategies for treating MRSA infections. One strategy targets a trough level of 10 to 15mg/L, while the other targets an AUC/MIC of 400 to 600. The primary outcome will be treatment failure, which is a composite of mortality and microbiologic failure at 90 days. The trial will determine if targeting a trough level of 10 to 15mg/L is non-inferior to targeting an AUC/MIC of 400 to 600 in terms of treatment failure.
Oral Antibiotics for Prosthetic Joint Infections
This trial is testing whether a 7-day course of an oral, prophylactic antibiotic can reduce the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk patient population.
Hygiene protocol for Staph Infection
The overall goal of the project is to develop and evaluate a home-based intervention to prevent re-infection and transmission of Community-Acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA) in patients presenting to primary care with skin or soft tissue infections (SSTIs). Centers for Disease Control (CDC) CA-MRSA guidelines include incision and drainage, antibiotic sensitivity testing and antibiogram-directed prescribing. Re-infections are common, ranging from 16% to 43%, and present significant challenges to clinicians, patients and their families. Several decolonization and decontamination interventions have been shown to reduce Hospital-Acquired MRSA (HA-MRSA) re-infection and transmission in intensive care units. Few studies examine the feasibility and effectiveness of these infection prevention interventions into primary care settings, and none employ Community Health Workers (CHWs) or "promotoras" to provide home visits for education and interventions about decolonization and decontamination. This comparative effectiveness research/patient centered outcomes research builds upon a highly stakeholder-engaged community-academic research and learning collaborative, including practicing clinicians, patients, clinical and laboratory researchers, and barbers/beauticians. Clinical Directors Network (CDN), an established, NIH-recognized best practice Federally Qualified Health Center (FQHC) Practice-based Research Network (PBRN), and The Rockefeller University propose to address this question through the completion of four aims: (1) To evaluate the comparative effectiveness of a CHW/Promotora-delivered home intervention (Experimental Group) as compared to Usual Care (Control Group) on the primary patient-centered and clinical outcome (SSTI recurrence rates) and secondary patient-centered and clinical outcomes (pain, depression, quality of life, care satisfaction) using a two-arm randomized controlled trial (RCT). (2) To understand the patient-level factors (CA-MRSA infection prevention knowledge, self-efficacy, decision-making autonomy, prevention behaviors/adherence) and environmental-level factors (household surface contamination, household member colonization, transmission to household members) that are associated with differences in SSTI recurrence rates. (3) To understand interactions of the intervention with bacterial genotypic and phenotypic variables on decontamination, decolonization, SSTI recurrence, and household transmission. (4) To explore the evolution of stakeholder engagement and interactions among patients and other community stakeholders with practicing community-based clinicians and academic laboratory and clinical investigators over the duration of the study period.
Frequently Asked Questions
Introduction to mrsa
What are the top hospitals conducting mrsa research?
When it comes to tackling the challenging threat of Methicillin-resistant Staphylococcus aureus (MRSA), several hospitals are leading the charge in clinical trials. In Philadelphia, the Hospital of the University of Pennsylvania is at the forefront with one active MRSA trial. While they may not have conducted any previous trials for this specific condition, their expertise and dedication to research make them a trusted institution in fighting against MRSA. Similarly, Hamilton Health Sciences and St. Joseph's Healthcare Hamilton in Hamilton both have one ongoing MRSA trial each but haven't previously conducted any studies on this particular antibiotic-resistant bacteria. Kingston Health Sciences Centre in Kingston also joins this league with an active MRSA trial and no prior investigations recorded.
Moreover, stepping up to combat MRSA is the University of Arkansas for Medical Sciences located in Little Rock. With one current clinical trial focusing on this formidable bacterium, they too lack a history of past studies dedicated solely to MRSA.
These hospitals' commitment to undertaking current trials signifies their determination to find effective solutions against this persistent infection that continues to pose challenges within healthcare facilities worldwide. Though relatively fewer trials exist for MRSA when compared to other conditions, these institutions serve as beacons of hope for patients affected by antimicrobial resistance while demonstrating that every effort counts towards combating such resilient pathogens
Which are the best cities for mrsa clinical trials?
When it comes to MRSA clinical trials, several cities are at the forefront of research and innovation. Brooklyn, New york leads with 3 active trials investigating decolonization and decontamination methods among other treatments. Philadelphia, Pennsylvania follows closely with 2 ongoing studies focusing on VRE lipopeptide and chlorhexidine interventions. Hamilton, Ontario also hosts 2 active trials exploring vancomycin therapy alongside other approaches. Lastly, Baltimore, Maryland and Saint Louis, Missouri each have 2 active trials studying various treatment options including chlorhexidine. These cities provide valuable opportunities for individuals seeking participation in MRSA clinical trials to contribute to advancements in finding effective treatments for this challenging infection.
Which are the top treatments for mrsa being explored in clinical trials?
In the realm of MRSA treatment, one particular contender stands out in clinical trials. Vancomycin, a potent antibiotic introduced in 2004, is currently being explored in an active trial focused on combating MRSA. With six all-time trials dedicated to this challenging infection, vancomycin holds promise as a leading option for tackling MRSA and offering hope to patients affected by it.
What are the most recent clinical trials for mrsa?
Exciting advancements in the fight against MRSA are underway with recent clinical trials offering hope for improved treatment options. One such trial focuses on VRE lipopeptide, a potential breakthrough in combating MRSA infections. With Phase 2 results becoming available on September 1st, 2023, researchers are optimistic about its efficacy. Additionally, another study explores the use of chlorhexidine as a means to combat MRSA infections. Having reached Phase 4 and made available on May 1st, 2023, this trial provides valuable insights into the effectiveness of this approach. These pioneering investigations highlight the ongoing dedication to finding new strategies to tackle MRSA head-on and improve patient outcomes.
What mrsa clinical trials were recently completed?
Recently completed clinical trials focused on combating MRSA infections have made significant strides in the field of medical research. These trials bring hope for improved treatments against this challenging bacteria. Although specific details are limited, recent studies indicate that multiple clinical trials targeting MRSA were successfully concluded. The completion of these trials signifies progress in the development of novel therapies to combat MRSA and highlights ongoing efforts to address this pressing healthcare issue.